Enhanced tuberculosis clearance through the combination treatment with recombinant adenovirus-mediated granulysin delivery.

Tuberculosis (TB) remains the leading cause of death among infectious diseases worldwide. Poor compliance of TB patients to the lengthy treatment increases the risk of relapse and leads to the emergence of multidrug-resistant and extensively drug-resistant TB (MDR-TB and XDR-TB). More effective therapies for TB are urgently needed. We hypothesized that granulysin-mediated clearance of parasited inside and outside of alveolar macrophages in presumptive infected hosts might enhance the chemotherapeutic efficacy on TB. Recombinant adenovirus type 5 (rAd5) based therapeutic vaccines rAdhGLi and rAdhGLs (rAds) were respectively developed to express intracellular and extracellular granulysin. The bactericidal effects of rAdhGLi and rAdhGLs were evaluated on U937 and RAW264.7 cells. The efficacy of immunotherapy with both rAdhGLi and rAdhGLs on TB SCID mice, or immunotherapy combined with chemotherapy on drug-susceptible TB or MDR-TB mouse models were further evaluated. rAdhGLs, as well as rAdhGLi, showed a direct bactericidal effect on extracellular or intracellular H37Rv and MDR-TB clinical strains, respectively. Immunotherapy with a dose of 10 PFU of rAdhGLi and 10 PFU of rAdhGLs demonstrated a more significant bactericidal effect on H37Rv infected SCID mice and prolonged their survival periods than rAdhGLi or rAdhGLs alone. More importantly, chemotherapy combined with rAds immunotherapy shortened the chemotherapeutic duration to 4 months on H37Rv infected mice and prevented the relapse. Combination of rAds with chemotherapy on MDR-TB mice also more significantly decreased organ bacterial load than their single use. Delivery of granulysin by recombinant adenovirus to the infected lung could enhance the clearance of TB and might be a promising adjunct therapeutic vaccine for TB and MDR-TB.